Cis-cyclopropylamines as mechanism-based inhibitors of monoamine oxidases

FEBS Journal

Volumn 282, Issue 16, 2015, Pages 3190-3198

  Malcomson, Thomas ^a   Yelekci, Kemal ^b   Borrello, Maria Teresa ^c   Ganesan, A ^c   Semina, Elena ^d   De Kimpe, Norbert ^d   Mangelinckx, Sven ^d   Ramsay, Rona R ^a  

^a UNIVERSITY OF ST ANDREWS   (United Kingdom)

^b KADIR HAS UNIVERSITY   (Turkey)

^c UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^d GHENT UNIVERSITY   (Belgium)

Author keywords

cyclopropylamine; docking; flavin adduct; mechanism based inhibitor; monoamine oxidase

Indexed keywords

2 METHOXY 2 METHYLCYCLOPROPYLAMINE; ALIPHATIC AMINE; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; CLORGYLINE; CYCLOPROPYLAMINE; CYCLOPROPYLAMINE DERIVATIVE; LYSINE SPECIFIC DEMETHYLASE; MONOAMINE OXIDASE INHIBITOR; N BENZYL 2 METHOXYCYCLOPROPYLAMINE; SELEGILINE; TRANYLCYPROMINE; UNCLASSIFIED DRUG; UNCLASSIFIED ENZYME; AMINE OXIDASE (FLAVIN CONTAINING); ANTIDEPRESSANT AGENT; CYCLOPROPANE DERIVATIVE; HISTONE DEMETHYLASE; KDM1A PROTEIN, HUMAN;

ARTICLE; BLEACHING; CHEMICAL MODIFICATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DESIGN; DRUG EFFICACY; DRUG POTENCY; DRUG RESEARCH; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENANTIOMER; ENZYME ACTIVITY; ENZYME INACTIVATION; ENZYME INHIBITION; ENZYME KINETICS; ENZYME SPECIFICITY; IC50; INCUBATION TIME; INHIBITION KINETICS; MOLECULAR DOCKING; MOLECULAR MODEL; PRIORITY JOURNAL; RACEMIC MIXTURE; STRUCTURE ACTIVITY RELATION; ANTAGONISTS AND INHIBITORS; CHEMICAL STRUCTURE; CHEMISTRY; ENZYME ACTIVE SITE; HUMAN; IN VITRO STUDY; KINETICS; METABOLISM; STEREOISOMERISM;

ANTIDEPRESSIVE AGENTS; CATALYTIC DOMAIN; CYCLOPROPANES; HISTONE DEMETHYLASES; HUMANS; IN VITRO TECHNIQUES; KINETICS; MODELS, MOLECULAR; MONOAMINE OXIDASE; MONOAMINE OXIDASE INHIBITORS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; TRANYLCYPROMINE;

EID: 84939250541     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/febs.13260     Document Type: Article

References (48)

1. Lee MG, Wynder C, Schmidt DM, McCafferty DG, &, Shiekhattar R, (2006) Histone H3 lysine 4 demethylation is a target of nonselective antidepressive medications. Chem Biol 13, 563-567.
2. Schmidt DMZ, &, McCafferty DG, (2007) trans-2-Phenylcyclopropylamine is a mechanism-based inactivator of the histone demethylase LSD1. Biochemistry 46, 4408-4416.
3. Youdim MBH, Edmondson D, &, Tipton KF, (2006) The therapeutic potential of monoamine oxidase inhibitors. Nat Rev Neurosci 7, 295-309.
4. Khan MNA, Suzuki T, &, Miyata N, (2013) An overview of phenylcyclopropylamine derivatives: biochemical and biological significance and recent developments. Med Res Rev 33, 873-910.
5. Binda C, Valente S, Romanenghi M, Pilotto S, Cirilli R, Karytinos A, Ciossani G, Botrugno OA, Forneris F, Tardugno M, et al,. (2010) Biochemical, structural, and biological evaluation of tranylcypromine derivatives as inhibitors of histone demethylases LSD1 and LSD2. J Am Chem Soc 132, 6827-6833.
6. Mimasu S, Sengoku T, Fukuzawa S, Umehara T, &, Yokoyama S, (2008) Crystal structure of histone demethylase LSD1 and tranylcypromine at 2.25 Å. Biochem Biophys Res Commun 366, 15-22.
7. Szewczuk LM, Culhane JC, Yang M, Majumdar A, Yu H, &, Cole PA, (2007) Mechanistic analysis of a suicide inactivator of histone demethylase LSD1. Biochemistry 46, 6892-6902.
8. Yang M, Culhane JC, Szewczuk LM, Jalili P, Ball HL, Machius M, Cole PA, &, Yu H, (2007) Structural basis for the inhibition of the LSD1 histone demethylase by the antidepressant trans-2-phenylcyclopropylamine. Biochemistry 46, 8058-8065.
9. Vianello P, Botrugno OA, Cappa A, Ciossani G, Dessanti P, Mai A, Mattevi A, Meroni G, Minucci S, Thaler F, et al,. (2014) Synthesis, biological activity and mechanistic insights of 1-substituted cyclopropylamine derivatives: a novel class of irreversible inhibitors of histone demethylase KDM1A. Eur J Med Chem 86, 352-363.
10. Hellerman L, &, Erwin VG, (1968) Mitochondrial monoamine oxidase. II. Action of various inhibitors for the bovine kidney enzyme. Catalytic mechanism. J Biol Chem 243, 5234-5243.
11. Collins GG, Youdim MB, &, Sandler M, (1972) Multiple forms of monoamine oxidase. Comparison of in vitro and in vivo inhibition patterns. Biochem Pharmacol 21, 1995-1998.
12. Morris JB, &, Beck AT, (1974) Efficacy of antidepressant drugs-a review of research (1958 to 1972). Arch Gen Psychiatry 30, 667-674.
13. Culhane JC, Wang D, Yen PM, &, Cole PA, (2010) Comparative analysis of small molecules and histone substrate analogues as LSD1 lysine demethylase inhibitors. J Am Chem Soc 132, 3164-3176.
14. Johnson NW, Kasparec J, Miller WH, Rouse MB, Suarez D, Tian X, Dominic S, Jiri K, Meagan RB, Neil JW, et al,. (2012) New substituted cyclopropylamine compounds useful for treating cancer e.g. glioblastomas, Bannayan-Zonana syndrome, Cowden disease, inflammatory breast cancer, Wilm's tumor, Ewing's sarcoma, and giant cell tumor of bone and thyroid. WO2012135113-A2; Glaxosmithkline Llc (GLAX-C).
15. Ortega Munoz A, Fyfe MCT, Martinell Pedemonte M, Estiarte Martinez MDL, Valls Vidal N, Kurz G, Castro Palomino Laria JC, Ortega MA, Martinell PM, Estiarte MMDL, et al,. (2013) New (hetero)aryl cyclopropylamine compound, useful for treating cancer, Alzheimer's disease, Huntington disease, Parkinson's disease, herpesvirus infection and viral reactivation after latency. WO2013057322-A1; Oryzon Genomics SA (ORYZ-Non-standard).
16. Lynch JT, Harris WJ, &, Somervaille TCP, (2012) LSD1 inhibition: a therapeutic strategy in cancer? Exp Opin Therap Targ 16, 1239-1249.
17. Lee HT, Choi MR, Doh MS, Jung KH, &, Chai YG, (2013) Effects of the monoamine oxidase inhibitors pargyline and tranylcypromine on cellular proliferation in human prostate cancer cells. Oncol Rep 30, 1587-1592.
18. Zeller EA, &, Sarkar S, (1962) Amine oxidases. XIX. Inhibition of monoamine oxidase by phenylcyclopropylamines and iproniazid. J Biol Chem 237, 2333-2336.
19. Zirkle CL, Kaiser C, Tedeschi DH, Tedeschi RE, &, Burger A, (1962) 2-Substituted cyclopropylamines. II. Effect of structure upon monoamine oxidase-inhibitory activity as measured in vivo by potentiation of tryptamine convulsions. J Med Pharmaceut Chem 91, 1265-1284.
20. Kang GI, &, Hong SK, (1990) Quantitative structure-activity relationships in MAO-inhibitory 2-phenylcyclopropylamines: insights into the topography of MAO-A and MAO-B. Arch Pharmacal Res (Seoul) 13, 82-96.
21. Moises HW, &, Beckmann H, (1981) Anti-depressant efficacy of tranylcypromine isomers-a controlled study. J Neural Transm 50, 185-192.
22. Benelkebir H, Hodgkinson C, Duriez PJ, Hayden AL, Bulleid RA, Crabb SJ, Packham G, &, Ganesan A, (2011) Enantioselective synthesis of tranylcypromine analogues as lysine demethylase (LSD1) inhibitors. Bioorg Med Chem 19, 3709-3716.
23. Mangelinckx S, Kadam ST, Semina E, Callebaut G, Colpaert F, De Smaele D, &, De Kimpe N, (2013) Synthesis of cis-2-alkoxycyclopropylamines via intramolecular cyclization of 2-azaallylic anions derived from alkoxybrominated N-(arylidene)-2-methyl-2-propenylamines. Tetrahedron 69, 3728-3735.
24. Youdim MB, Collins GG, Sandler M, Bevan Jones AB, Pare CM, &, Nicholson WJ, (1972) Human brain monoamine oxidase: multiple forms and selective inhibitors. Nature 236, 225-228.
25. Sherry RL, Baker GB, Coutts RT, &, Mousseau DD, (1990) Ring-substituted analogues of tranylcypromine as monoamine oxidase inhibitors. J Neural Transm (Suppl) 32, 107-112.
26. Bonivento D, Milczek EM, McDonald GR, Binda C, Holt A, Edmondson DE, &, Mattevi A, (2010) Potentiation of ligand binding through cooperative effects in monoamine oxidase B. J Biol Chem 285, 36849-36856.
27. McDonald GR, Olivieri A, Ramsay RR, &, Holt A, (2010) On the formation and nature of the imidazoline I(2) binding site on human monoamine oxidase-B. Pharmacol Res 62, 475-488.
28. Basile L, Pappalardo M, Guccione S, Milardi D, &, Ramsay RR, (2014) Computational comparison of imidazoline association with the 12 binding site in human monoamine oxidases. J Chem Inf Model 54, 1200-1207.
29. Gokhan-Kelekci N, Simsek OO, Ercan A, Yelekci K, Sahin ZS, Isik S, Ucar G, &, Bilgin AA, (2009) Synthesis and molecular modeling of some novel hexahydroindazole derivatives as potent monoamine oxidase inhibitors. Bioorg Med Chem 17, 6761-6772.
30. Morris GM, Goodsell DS, Halliday RS, Huey R, Hart WE, Belew RK, &, Olson AJ, (1998) Automated docking using a Lamarckian genetic algorithm and empirical binding free energy function. J Comp Chem 19, 1639-1662.
31. Trott O, &, Olson AJ, (2010) AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem 31, 455-461.
32. Ramsay RR, Olivieri A, &, Holt A, (2011) An improved approach to steady-state analysis of monoamine oxidases. J Neural Transm 118, 1003-1019.
33. Kitz R, &, Wilson IB, (1962) Esters of methanesulfonic acid as irreversible inhibitors of acetylcholinesterase. J Biol Chem 237, 3245-3249.
34. Edmondson DE, Binda C, &, Mattevi A, (2007) Structural insights into the mechanism of amine oxidation by monoamine oxidases A and B. Arch Biochem Biophys 464, 269-276.
35. Binda C, Newton-Vinson P, Hubalek F, Edmondson DE, &, Mattevi A, (2002) Structure of human monoamine oxidase B, a drug target for the treatment of neurological disorders. Nat Struct Biol 9, 22-26.
36. De Colibus L, Li M, Binda C, Lustig A, Edmondson DE, &, Mattevi A, (2005) Three-dimensional structure of human monoamine oxidase A (MAO A): relation to the structures of rat MAO A and human MAO B. Proc Natl Acad Sci USA 102, 12684-12689.
37. Vintem A-PB, Ramsay RR, &, Silverman RB, (2002) Subtle differences between MAO A and its cysteine 374 mutant during mechanism-based inactivation by cyclopropylamines. In Flavins and Flavoproteins 2002 (, Chapman SK, Perham RN, &, Scrutton NS, eds), pp. 911-915. Rudolph Weber, Berlin.
38. Esteban G, Allan J, Samadi A, Mattevi A, Unzeta M, Marco-Contelles J, Binda C, &, Ramsay RR, (2014) Kinetic and structural analysis of the irreversible inhibition of human monoamine oxidases by ASS234, a multi-target compound designed for use in Alzheimer's disease. Biochim Biophys Acta 1844, 1104-1110.
39. Vintem APB, Price NT, Silverman RB, &, Ramsay RR, (2005) Mutation of surface cysteine 374 to alanine in monoamine oxidase A alters substrate turnover and inactivation by cyclopropylamines. Bioorg Med Chem 13, 3487-3495.
40. Mitchell DJ, Nikolic D, van Breemen RB, &, Silverman RB, (2001) Inactivation of monoamine oxidase B by 1-phenylcyclopropylamine: mass spectral evidence for the flavin adduct. Bioorg Med Chem Lett 11, 1757-1760.
41. Silverman RB, (1995) Radical ideas about monoamine-oxidase. Accounts Chem Res 28, 335-342.
42. Mimasu S, Umezawa N, Sato S, Higuchi T, Umehara T, &, Yokoyama S, (2010) Structurally designed trans-2-phenylcyclopropylamine derivatives potently inhibit histone demethylase LSDI/KDM1. Biochemistry 49, 6494-6503.
43. Chen J, Levant B, Jiang C, Keck TM, Newman AH, &, Wang S, (2014) Tranylcypromine substituted cis-hydroxycyclobutylnaphthamides as potent and selective dopamine D3 receptor antagonists. J Med Chem 57, 4962-4968.
44. Edmondson DE, Binda C, Wang J, Upadhyay AK, &, Mattevi A, (2009) Molecular and mechanistic properties of the membrane-bound mitochondrial monoamine oxidases. Biochemistry 48, 4220-4230.
45. Mitchell DJ, Silverman RB, Singer TP, Sablin SO, van Breemen RB, Nikolic D, &, Rivera E, (2000) Nuclear magnetic resonance and mass spectroscopic evidence for the flavin-1-phenylcyclopropylamine inactivator adduct of monoamine oxidase. Abstr Pap Am Chem Soc. 219, 52- BIOL.
46. Zhou MJ, &, PanchukVoloshina N, (1997) A one-step fluorometric method for the continuous measurement of monoamine oxidase activity. Anal Biochem 253, 169-174.
47. Holt A, &, Palcic MM, (2006) A peroxidase-coupled continuous absorbance plate-reader assay for flavin monoamine oxidases, copper-containing amine oxidases and related enzymes. Nat Protoc 1, 2498-2505.
48. Pollak Y, Mechlovich D, Amit T, Bar-Am O, Manov I, Mandel SA, Weinreb O, Meyron-Holtz EG, Iancu TC, &, Youdim MBH, (2013) Effects of novel neuroprotective and neurorestorative multifunctional drugs on iron chelation and glucose metabolism. J Neural Transm 120, 37-48.